丙型肝炎病毒操纵人类作为其长期关系的首选宿主
丙型肝炎病毒(HCV)慢性感染相关的肝病是全球健康问题,常呈隐匿性并最终进展为终末期肝病。HCV感染肝细胞,但肝病最初表现主要在肝星状细胞(HSC),引起纤维化/肝硬化,并被认为源于肝脏炎症。尚不清楚为何多数个体不能自发清除HCV并发展为慢性感染伴进行性肝病。直接抗病毒药物(DAA)在控制病毒血症方面效果优异,但对晚期肝病的获益尚待了解。本综述重点介绍当前关于HCV在炎症、免疫逃逸、代谢紊乱、肝脏病理发生及疫苗研发努力中作用的认识。
要点
- HCV慢性感染常隐匿起病,最终进展为终末期肝病。
- 肝病初始表现主要在肝星状细胞,引起纤维化/肝硬化,被认为源于肝脏炎症。
- DAA控制病毒血症效果优异,但对晚期肝病的获益尚待了解。
核心结论
- 本综述重点介绍当前关于HCV在炎症、免疫逃逸、代谢紊乱、肝脏病理发生及疫苗研发努力中作用的认识。
研究设计与样本
- 综述,检索范围原文未报告。
主要发现
- HCV感染肝细胞,但肝病初始表现主要在肝星状细胞(HSC),引起纤维化/肝硬化,并被认为源于肝脏炎症。
- 尚不清楚为何多数个体不能自发清除HCV并发展为慢性感染伴进行性肝病。
- DAA在控制病毒血症方面效果优异,但对晚期肝病的获益尚待了解。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Chronic hepatitis C virus (HCV) infection-associated liver disease is a global health problem. HCV often causes silent disease, and eventually progresses to end-stage liver disease. HCV infects hepatocytes; however, initial manifestation of liver disease is mostly displayed in hepatic stellate cells (HSCs), causing fibrosis/cirrhosis, and is believed to occur from inflammation in the liver. It remains unclear why HCV is not spontaneously cleared from infected liver in the majority of individuals and develops chronic infection with progressive liver disease. Direct-acting antivirals (DAAs) show excellent results in controlling viremia, although beneficial consequence in advanced liver disease remains to be understood. In this review, we highlight the current knowledge that has contributed to our understanding of the role of HCV in inflammation, immune evasion, metabolic disorders, liver pathogeneses, and efforts in vaccine development.
引用
- Ray RB, Ray R. Hepatitis C Virus Manipulates Humans as its Favorite Host for a Long-Term Relationship. Hepatology. 2019. PMID: 30102776. doi:10.1002/hep.30214
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。